Closure Omnex Helps Seal 20% Stock Rebound In October – OTC Index
This article was originally published in The Gray Sheet
Executive Summary
Investor optimism that Closure Medical will achieve strong revenue growth following the pending launch of its Omnex surgical vascular sealant in Europe helped the firm's stock rise 19.8% to $17.06 in October
You may also be interested in...
J&J Seals Deal With Closure, Acquires OmNex Maker For $370 Mil.
Johnson & Johnson's agreement to purchase Closure Medical for $370 mil. on March 4 comes nine days after the latter firm's OmNex surgical sealant received CE mark in Europe
J&J Seals Deal With Closure, Acquires OmNex Maker For $370 Mil.
Johnson & Johnson's agreement to purchase Closure Medical for $370 mil. on March 4 comes nine days after the latter firm's OmNex surgical sealant received CE mark in Europe
Digene Stock Rebound Could Continue In 2005; OTC Index Ahead 23%
Digene's increased focus on physician detailing for its DNAwithPap human papillomavirus test, coupled with plans for consumer advertising, could allow the firm to exceed recently revised growth expectations